Eurogentec

Seraing, Belgium Founded: 1985 • Age: 41 yrs Acquired By Kaneka
Oligonucleotides, peptides, and antibodies are developed and manufactured by Eurogentec.
Annual revenue $113.6M Latest available
Total funding - 6 rounds
Employees 426 Tracked headcount
Investors 2 Known backers
Products 4 Services tracked
Competitors 8 Brand Intelligence

About Eurogentec

Eurogentec is a company based in Seraing (Belgium) founded in 1985 was acquired by Kaneka in June 2010. The company has 426 employees as of March 31, 2023. Eurogentec has completed 1 acquisition, including AnaSpec. Eurogentec offers products and services including Oligos, PCR Kits, Antibodies, and Peptides. Eurogentec operates in a competitive market with competitors including Nephron Pharmaceuticals, Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm and Suanfarma, among others.

  • Headquarter Seraing, Belgium
  • Employees 426 as on 31 Mar, 2023
  • Sectors
    Healthcare
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Kaneka Eurogentec
Operational Areas
Healthcare → Healthcare Services & Infrastructure Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    $113.57 M (USD)
    21
    as on Mar 31, 2023
  • Net Profit
    $14.39 M (USD)
    24
    as on Mar 31, 2023
  • EBITDA
    $27.36 M (USD)
    26
    as on Mar 31, 2023
  • Latest Funding Round
    $51.55 K (USD), Grant

    Sep 01, 2023

  • Investors
  • Employee Count
    426

    as on Mar 31, 2023

  • Investments & Acquisitions
  • Acquired by
    Kaneka

    (Jun 15, 2010)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Eurogentec

Eurogentec offers a comprehensive portfolio of products and services, including Oligos, PCR Kits, Antibodies, and Peptides.

Product name locked
Category locked
Primary

Custom synthesized oligonucleotides for research and diagnostics applications.

Product name locked
Category locked
Locked

Kits for quantitative PCR assays in gene analysis.

Product name locked
Category locked
Locked

Custom polyclonal and monoclonal antibodies for protein detection.

Product name locked
Category locked
Locked

Synthesized peptides for research and therapeutic uses.

Funding Insights of Eurogentec

Investors in Eurogentec

Eurogentec has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include European Union and Kaneka.

All
Institutional
Investor Description Founded Year Domain Location
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
Locked Locked Locked
Chemical products are produced for diverse industrial applications.
Locked Locked Locked
Premium access

Investor details for Eurogentec

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by Eurogentec

Eurogentec has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include AnaSpec.

Investments
Premium access

Investment portfolio details for Eurogentec

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Acquisitions
Company Name Description Domain Location Founded Year Amount
Premier provider of reagents and services for research, HTP screening, and drug discovery. Services include peptide/oligo synthesis, Ab prod., and assay dev.
Locked Locked 1993 Locked
Premium access

Complete acquisition details for Eurogentec

Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.

  • Transaction dates
  • Acquired stakes
  • Disclosed values
  • Domains and locations

Verified entity values are shown only after access is granted.

Financial Statements - Eurogentec

Premium access

Detailed financials for Eurogentec

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Eurogentec Comparisons

Eurogentec Primary company
Description
Oligonucleotides, peptides, and antibodies are developed and...
Location
Seraing, Belgium
Founded Year
1985
Annual Revenue
$113.57 M (USD)
Net Profit
$14.39 M (USD)
EBITDA
$27.36 M (USD)
Employees
426
As of 2023
Premium access

Peer comparison for Eurogentec

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of Eurogentec

Eurogentec operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nephron Pharmaceuticals, Enzene Biosciences, Hybio Pharmaceutical, AmbioPharm and Suanfarma, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Sterile pharmaceutical products are manufactured and contract services are provided.
Locked Locked Locked
Company specializing in development of Biosimilars
Locked Locked Locked
Polypeptide drugs and APIs are developed and manufactured.
Locked Locked Locked
CDMO and analytical services for peptide development are provided.
Locked Locked Locked
Generics, nutraceuticals, and APIs are developed by Suanfarma.
Locked Locked Locked
Biotech company developing personalized medicines for cardiovascular diseases
Premium access

Detailed competitors of Eurogentec

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Eurogentec

Premium access

Complete news archive for Eurogentec

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Eurogentec

Eurogentec was founded in 1985 and raised its 1st funding round 30 years after it was founded.

Eurogentec is headquartered in Seraing, Belgium. It is registered at Seraing, Liege, Belgium.

As of Mar 31, 2023, the latest employee count at Eurogentec is 426.

Annual revenue of Eurogentec is $113.57M as on Mar 31, 2023.

Eurogentec S.A., is a leading global supplier of innovative reagents, kits, specialty products and custom services. It has three inter-related business units (BU). Life Science Research BU is specialized in innovative solutions in Genomics and Proteomics, through which it supplies a wide range of reagents, kits and consumables for Life Science applications such as Custom Oligonucleotides, high performance PCRqPCR Kits Reagents, catalogue dyes, peptides antibodies. It also offers custom synthesis of petides and antibodies. The Diagnostic Services BU provides technical and project support for contract manufacturing of GMP oligonucleotides and Taq DNA polymerases. The GMP BioManufacturing BU is a US FDA inspected full-service Contract Manufacturing Organization (CMO). It offers expertise in technology transfer, process development, scale-up and cGMP manufacturing of proteins, protein conjugates, plasmid DNA and bacterial vaccines for pre-clinical, clinical and commercial uses. They claim to be experts in microbial cell lines (E.coli, P. pastoris etc.,) and also to have developed over 100 different GMP biopharmaceuticals since 1994. In 2009, Eurogentec acquired AnaSpec, a provider of integrated proteomics solutions for life science research and diagnostics. In 2010, Eurogentec became part of Kaneka Corporation, Osaka, Japan, a chemical company active in polymers, fermentation, biotechnology and electronics, as well as other fields.

Eurogentec's top competitors include Nephron Pharmaceuticals, Suanfarma and Enzene Biosciences.

Eurogentec offers Oligos, PCR Kits, Antibodies, and Peptides.

Eurogentec has made 1 acquisition, including AnaSpec.

Eurogentec has 2 investors. Key investors include European Union, and Kaneka.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available